Inozyme Pharma
INZY
INZY was delisted on the 30th of June, 2025.
74 hedge funds and large institutions have $190M invested in Inozyme Pharma in 2023 Q2 according to their latest regulatory filings, with 33 funds opening new positions, 25 increasing their positions, 12 reducing their positions, and 8 closing their positions.
313% more first-time investments, than exits
New positions opened: 33 | Existing positions closed: 8
108% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 12
51% more funds holding
Funds holding: 49 → 74 (+25)
4.4% more ownership
Funds ownership: 73.16% → 77.56% (+4.4%)
4% more capital invested
Capital invested by funds: $183M → $190M (+$6.85M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
52% less call options, than puts
Call options by funds: $126K | Put options by funds: $263K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$8.8M |
| 2 |
Millennium Management
New York
|
+$3.04M |
| 3 |
State Street
Boston,
Massachusetts
|
+$2.74M |
| 4 |
PBPIA
Pivotal bioVenture Partners Investment Advisor
San Francisco,
California
|
+$2.65M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
-$9.49M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$3.84M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$3.83M |
| 4 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.89M |
| 5 |
CA
CHI Advisors
New York
|
-$870K |
INZY Hedge Fund Activity: Q2 2023 in Review
74 of the 6,370 institutional investors tracked by Wall St. Rank reported a position in Inozyme Pharma (INZY) for Q2 2023, worth a combined $190M — up 3.7% from $183M a quarter earlier.
Buyers outnumbered sellers: 33 funds opened new INZY positions and 8 closed out — a net gain of 25 holders — while 25 added to existing stakes and 12 trimmed.
The largest buyer was BlackRock, adding an estimated $8.8M. The largest seller was Deep Track Capital, cutting an estimated $9.49M.
- 74 institutional investors held Inozyme Pharma (INZY) as of Q2 2023, up from 49 in Q1 2023.
- Funds reported $190M of Inozyme Pharma stock for Q2 2023, up 3.7% quarter-over-quarter.
- 33 funds opened new Inozyme Pharma positions in Q2 2023 and 8 closed out, a net change of +25 holders.
- The largest Inozyme Pharma buyer in Q2 2023 was BlackRock, an estimated $8.8M added.
- The largest Inozyme Pharma seller in Q2 2023 was Deep Track Capital, an estimated $9.49M sold.
Based on aggregated 13F filings for Q2 2023.